A Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery was associated with a significant decrease in the progression of chronic ...

A new study, led by Professor John Deanfield from University College London (UCL), reveals that the anti-obesity medication ...

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...

Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect ...

Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

but they do not contain GLP-1. They do not contain an agonist or a mimicking hormone,” Raj said in a TODAY segment that aired on Thursday, Sept. 19. “They contain extracts, maybe from fruits or ...

For significant weight loss, Zepbound may be the better option. If you have Type 2 diabetes and are looking for a dual ...

Weight loss and maintenance related to the mechanism of action of glucagon-like peptide ... Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study ...

While ants live forever thanks to a little parasite, humans are too busy popping GLP-1s and obsessively organizing their ...

Semaglutide and tirzepatide are both glucagon-like peptide-1 receptor agonists or GLP-1 agonists. Although originally prescribed to treat type 2 diabetes (Ozempic and Mounjaro), semaglutide and ...